GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for ...

The studies confirmed that the vaccine has a safety profile consistent with the licensed meningococcal vaccines of GSK. The ...

GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

(HealthDay News) — The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease (IMD), ...

UK pharma major GSK late Friday announced that the US Food and Drug Administration (FDA) has approved Penmenvy (meningococcal ...

Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

今日，市值748.8亿美元、毛利率高达71.81%的制药巨头GSK plc（LSE/NYSE: GSK）宣布完成对波士顿生物制药公司IDRx, Inc.的收购。此项交易总额可达11.5亿美元，包括10亿美元的首付款和潜在的里程碑付款。根据 InvestingPro 数据显示，GSK保持着强劲的财务健康状况，为战略收购奠定了良好基础。

GSK) today announced that the US Food and Drug Administration (FDA) has approved PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine) for use in individuals aged 10 through 25 years.

The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...